Skip to main content
Print Save

Generic Eucrisa Availability

Last updated on Mar 9, 2023.

Eucrisa is a brand name of crisaborole topical, approved by the FDA in the following formulation(s):

EUCRISA (crisaborole - ointment;topical)

  • Manufacturer: ANACOR PHARMS INC
    Approval date: December 14, 2016
    Strength(s): 2% [RLD]

Has a generic version of Eucrisa been approved?

No. There is currently no therapeutically equivalent version of Eucrisa available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Eucrisa. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: Generic Drug FAQ.

Related patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Boron-containing small molecules
    Patent 8,039,451
    Issued: October 18, 2011
    Inventor(s): Baker; Stephen J. & Akama; Tsutomu & Bellinger-Kawahara; Carolyn & Hernandez; Vincent S. & Hold; Karin M. & Leyden; James J. & Maples; Kirk & Plattner; Jacob J. & Sanders; Virginia & Zhang; Yong-Kang
    Assignee(s): Anacor Pharmaceuticals, Inc.

    This invention relates to compounds useful for treating fungal infections, more specifically topical treatment of onychomycosis and/or cutaneous fungal infections. This invention is directed to compounds that are active against fungi and have properties that allow the compound, when placed in contact with a patient, to reach the particular part of the skin, nail, hair, claw or hoof infected by the fungus. In particular the present compounds have physiochemical properties that facilitate penetration of the nail plate.

    Patent expiration dates:

    • June 29, 2029
      ✓ 
      Drug substance
      ✓ 
      Drug product
    • December 29, 2029
      ✓ 
      Pediatric exclusivity
  • Boron-containing small molecules as anti-inflammatory agents
    Patent 8,168,614
    Issued: May 1, 2012
    Inventor(s): Baker; Stephen J. & Sanders; Virginia & Akama; Tsutomu & Bellinger-Kawahara; Carolyn & Freund; Yvonne & Maples; Kirk R. & Plattner; Jacob J. & Zhang; Yong-Kang & Zhou; Huchen & Hernandez; Vincent S.
    Assignee(s): Anacor Pharmaceuticals, Inc.

    Methods of treating anti-inflammatory conditions through the use of boron-containing small molecules are disclosed.

    Patent expiration dates:

    • January 20, 2030
      ✓ 
      Patent use: METHOD OF TREATING MILD TO MODERATE ATOPIC DERMATITIS.
    • July 20, 2030
      ✓ 
      Pediatric exclusivity
  • Boron-containing small molecules as anti-inflammatory agents
    Patent 8,501,712
    Issued: August 6, 2013
    Assignee(s): Anacor Pharmaceuticals, Inc.

    Methods of treating anti-inflammatory conditions through the use of boron-containing small molecules are disclosed.

    Patent expiration dates:

    • February 16, 2027
      ✓ 
      Patent use: METHOD OF TREATING MILD TO MODERATE ATOPIC DERMATITIS.
    • August 16, 2027
      ✓ 
      Pediatric exclusivity
  • Boron-containing small molecules as anti-inflammatory agents
    Patent 9,682,092
    Issued: June 20, 2017
    Assignee(s): Anacor Pharmaceuticals, Inc.

    Methods of treating anti-inflammatory conditions through the use of boron-containing small molecules are disclosed.

    Patent expiration dates:

    • February 16, 2027
      ✓ 
      Patent use: METHOD OF TREATING MILD TO MODERATE ATOPIC DERMATITIS.
    • August 16, 2027
      ✓ 
      Pediatric exclusivity

Related exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

  • Exclusivity expiration dates:

    • March 23, 2023 - NEW PATIENT POPULATION
    • September 23, 2023 - PEDIATRIC EXCLUSIVITY

Glossary

Term Definition
Drug Patent A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug Exclusivity Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLD A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer